Pharmafile Logo
Pharmafocus logo
Advanced Search
shutterstock_244903099

“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK

February 19, 2019
Manufacturing and Production, Research and Development AKL Research and Development, Innovate UK, osteoarthritis, pharma

A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …

News
chinese_flag_beijing_-_img_1104

China to establish national rare disease network

February 19, 2019
Manufacturing and Production China, NHC, healthcare, rare diseases

China is set to establish a national collaborative network of hospitals for rare disease diagnosis and treatment to promote early …

News

Japanese researchers to trial stem cell therapy in four patients with serious spinal injuries

February 19, 2019
Manufacturing and Production Japan, Keio University, Parkinson's, cell therapy, iPS

The Japanese health ministry has approved a study testing the use of induced pluripotent stem (iPS) cells to treat four …

News
screen_shot_2019-01-29_at_15

Beating the flu

February 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus

On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …

Feature

Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer

February 18, 2019
Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …

News

Smoking may limit immune system’s ability to fight cancer, study shows

February 18, 2019
Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking

Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …

News
shutterstock_38078521

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

February 18, 2019
Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …

News

Researchers activate gene to reverse depression in mice

February 18, 2019
Sales and Marketing SIRT1, depression, genetics, mental health

Scientists at the Medical College of Georgia at Augusta University were able to directly activate a gene associated with depression …

News
merckwindow_web

MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

February 18, 2019
Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …

News
diabetes-777001_960_720

Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10

News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …

News

Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer

February 15, 2019
Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …

News

AstraZeneca to retire MedImmune brand amid restructuring

February 15, 2019
Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D …

News

Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

February 15, 2019
Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …

News
shutterstock_232245868

First asthma pill in two decades could treat condition by reducing airway muscle

February 14, 2019
Research and Development asthma, pharma

Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an …

News
takeda_usa_pharmaceuticals_u

Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

News

FDA approves Novartis’ Egaten for parasitic infection fascioliasis

February 14, 2019
Sales and Marketing Egaten, FDA, Novartis, fascioliasis, pharma

The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …

News
shutterstock_138095450

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

February 14, 2019
Sales and Marketing Clinigen, Novartis, Proleukin, pharma

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant …

News

J&J acquires lung cancer-focused robotics firm Auris Health in potential $5.75m deal

February 14, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Auris Health, Cancer, J&J, JJ, lung cancer, pharma, robotics

In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics …

News

BMS scores expanded European approval for Sprycel in paediatric leukaemia

February 13, 2019
Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma

Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026